Neurogen Corporation has reported promising results of its double-blind placebo-controlled Phase I clinical trial of its novel neuropeptide Y antagonist, NGD 95-1, for the treatment of eating disorders including obesity and binge eating.
The drug, developed in collaboration with Pfizer, was orally administered to 75 obese patients in a fed or fasted state in one of six doses, and was proved safe and well-tolerated. A maximum safe dose will now be sought, with Phase II trials anticipated to begin in mid-1997.
NPY has proved itself to be a potent stimulator of eating, and in animal studies Neurogen has demonstrated that NGD 95-1 reduced weight gain in normal rats.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze